<DOC>
	<DOCNO>NCT01637753</DOCNO>
	<brief_summary>The purpose study determine safety efficacy intracranially implanted Carmustine treatment patient recurrent malignant glioma .</brief_summary>
	<brief_title>Safety Efficacy Study Intracranially Implanted Carmustine Treat Recurrent Malignant Glioma</brief_title>
	<detailed_description>Malignant glioma recur mostly 2 cm within originated area . Local therapy therefore become particular important . Gliadel wafer develop States market developed country example treatment . The product study , Carmustine Sustained Release Implant ( CASANT ) , similar Gliadel wafer API ( Active Pharmaceutical Ingredient ) , different drug delivering system . As require , preliminary clinical study conduct China . Based result phase I/II , 8-10 wafer contain give dose BCNU administer intracranially phase III tumor resect cavity investigate safety efficacy treatment recurrent malignant glioma 212 patient .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Astrocytoma</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Oligodendroglioma</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<criteria>Patients must 18 70 year old , sign ICF ; At least 4 week previous chemotherapy ( 6 week since nitrosoureas ) ; KPS ≥ 60 ; Unilateral , Supratentorial , solitary lesion cross midline ( exclude patient little tumor near resectable tumor even investigator think single lesion ) No obvious important organ dysfunction : Blood routine : White blood cell ( WBC ) ≥ 4.0×109/L , Absolute neutrophil count ( ANC ) ≥ 1.5×109/L , Platelets≥ 100×109/L , Hemoglobin≥ 90 g/L ; Hepatic function : Serum total bilirubin ≤1.5 time upper limit laboratory normal ; Aspartate aminotransferase ( AST ) and/or Alanine aminotransferase ( ALT ) ＜2.5 time upper limit laboratory normal ; Renal function : Serum creatinine ≤1.5 time upper limit laboratory normal ; Not Pregnant lactate woman childbearing potential . Tumor locate ventricular system , Open ventricle tumor cavity postoperatively ; Concomitant lifethreatening diseases life expectancy ＜3 month ; Allergic nitrosourea drug ; With history intracranial radiotherapy implant chemotherapy ; With serious cardiac , pulmonary , hepatic renal dysfunction , poor glycemic control ; Investigators think unsuitable enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>